Device
LINX Reflux Management System
LINX Reflux Management System is a medical device with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Active, not recruiting1
Terminated1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 41 (100.0%)
Trials by Status
active_not_recruiting133%
terminated133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruiting
RETHINK REFLUX Registry
NCT04253392
terminated
LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm
NCT04695171
completedphase_4
The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
NCT02505945
Clinical Trials (3)
Showing 3 of 3 trials
NCT04253392
RETHINK REFLUX Registry
NCT04695171
LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm
NCT02505945Phase 4
The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
All 3 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 3